Amgen has terminated its participation in the co-development and commercialization of brodalumab under its collaboration with AstraZeneca after events of suicidal ideation and behavior in the brodalumab program, which the company believes would restrict labeling. Brodalumab, an investigational IL-17 inhibitor, is in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.    AstraZeneca will now be responsible for the clinical developme...